Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Dexmethylphenidate Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
30 September 2023
This article summarized the latest R&D progress of Dexmethylphenidate Hydrochloride, the Mechanism of Action for Dexmethylphenidate Hydrochloride, and the drug target R&D trends for Dexmethylphenidate Hydrochloride.
Latest Hotspot
3 min read
Nova Therapeutics confirms FDA approval of VNT-101's IND application, a new direct-acting antivirus targeting Influenza A virus
30 September 2023
Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.
Drug Insights
4 min read
Unleashing the Power of Colesevelam Hydrochloride: A Comprehensive Review on R&D Breakthroughs
30 September 2023
This article summarized the latest R&D progress of Colesevelam Hydrochloride, the Mechanism of Action for Colesevelam Hydrochloride, and the drug target R&D trends for Colesevelam Hydrochloride.
Valuable Targets
6 min read
Analysis on the Research Progress of PDE4 Inhibitors
30 September 2023
Phosphodiesterase 4 (PDE4) is an enzyme found in various tissues of the human body, including the immune cells, brain, and lungs.
Drug Insights
4 min read
A Comprehensive Review of Clindamycin Palmitate Hydrochloride's R&D Innovations
30 September 2023
This article summarized the latest R&D progress of Clindamycin Palmitate Hydrochloride, the Mechanism of Action for Clindamycin Palmitate Hydrochloride, and the drug target R&D trends for Clindamycin Palmitate Hydrochloride.
Latest Hotspot
3 min read
Merck's phase III KEYNOTE-A39/EV-302 trial halted disease progression in some new urothelial cancer patients
30 September 2023
Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.
Drug Insights
5 min read
Pharmaceutical Insights: Clemastine Fumarate's R&D Progress and its Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Clemastine Fumarate, the Mechanism of Action for Clemastine Fumarate, and the drug target R&D trends for Clemastine Fumarate.
Valuable Targets
4 min read
Analysis on the Clinical Research Progress of Prostaglandin Synthases Inhibitors
30 September 2023
Prostaglandin synthases are enzymes that play a crucial role in the human body by catalyzing the synthesis of prostaglandins.
Drug Insights
5 min read
Exploring Ciprofloxacin Hydrochloride's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Ciprofloxacin Hydrochloride, the Mechanism of Action for Ciprofloxacin Hydrochloride, and the drug target R&D trends for Ciprofloxacin Hydrochloride.
Latest Hotspot
3 min read
Genmab announces EU approval for TEPKINLY® (epcoritamab) to treat adult R/R DLBCL
30 September 2023
Genmab Unveils EU Commission's Authorization for TEPKINLY® (epcoritamab) to Treat Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in Adults.
Drug Insights
4 min read
Decoding Carboprost Tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
30 September 2023
This article summarized the latest R&D progress of Carboprost Tromethamine, the Mechanism of Action for Carboprost Tromethamine, and the drug target R&D trends for Carboprost Tromethamine.
Valuable Targets
6 min read
Advances in Clinical Research on PPAR Agonists
30 September 2023
PPAR, or peroxisome proliferator-activated receptor, is a group of nuclear receptor proteins found in the human body.